Success Metrics

Clinical Success Rate
84.2%

Based on 16 completed trials

Completion Rate
84%(16/19)
Active Trials
6(19%)
Results Posted
69%(11 trials)
Terminated
3(10%)

Phase Distribution

Ph phase_3
8
26%
Ph early_phase_1
1
3%
Ph phase_1
3
10%
Ph phase_4
5
16%
Ph not_applicable
3
10%
Ph phase_2
10
32%

Phase Distribution

4

Early Stage

10

Mid Stage

13

Late Stage

Phase Distribution30 total trials
Early Phase 1First-in-human
1(3.3%)
Phase 1Safety & dosage
3(10.0%)
Phase 2Efficacy & side effects
10(33.3%)
Phase 3Large-scale testing
8(26.7%)
Phase 4Post-market surveillance
5(16.7%)
N/ANon-phased studies
3(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

16 of 20 finished

Non-Completion Rate

20.0%

4 ended early

Currently Active

6

trials recruiting

Total Trials

31

all time

Status Distribution
Active(7)
Completed(16)
Terminated(4)
Other(4)

Detailed Status

Completed16
unknown4
Active, not recruiting4
Terminated3
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
6
Success Rate
84.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.3%)
Phase 13 (10.0%)
Phase 210 (33.3%)
Phase 38 (26.7%)
Phase 45 (16.7%)
N/A3 (10.0%)

Trials by Status

recruiting26%
terminated310%
not_yet_recruiting13%
withdrawn13%
unknown413%
completed1652%
active_not_recruiting413%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT03844061Phase 2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Recruiting
NCT03663933Phase 2

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

Active Not Recruiting
NCT04221477Phase 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

Active Not Recruiting
NCT05627557Phase 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Active Not Recruiting
NCT02722668Phase 2

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Completed
NCT06019507Phase 2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active Not Recruiting
NCT06279494Phase 1

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

Not Yet Recruiting
NCT02661035Phase 2

Allo HSCT Using RIC for Hematological Diseases

Completed
NCT03096275Phase 3

Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis

Completed
NCT05951517Not Applicable

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura

Recruiting
NCT05202145Phase 1

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Completed
NCT05423496Not Applicable

KidneyCare Immuno-optimization in Renal Allografts (KIRA)

Withdrawn
NCT05686746Phase 2

Use of Baricitenib to Maintain of Remission

Unknown
NCT03303989Phase 2

REduCing Immunogenicity to PegloticasE (RECIPE) Study

Completed
NCT00350181Phase 2

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Completed
NCT00001964Phase 2

Combination Therapy of Severe Aplastic Anemia

Completed
NCT02978274

Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation

Unknown
NCT04203108Phase 4

ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis

Unknown
NCT01544491Phase 3

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Completed
NCT02390362Phase 3

Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
31